PARKERVISION INC
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Summary Compensation Table
The following table summarizes the total compensation of each of our “named executive officers” as defined in Item 402(m) of Regulation S-K (the “Executives”) for the fiscal years ended December 31, 2024 and 2023. Given the complexity of disclosure requirements concerning executive compensation, and in particular with respect to the standards of financial accounting and reporting related to equity compensation, there is a difference between the compensation that is reported in this table versus that which is actually paid to and received by the Executives. The amounts in the Summary Compensation Table that reflect the full grant date fair value of an equity award, do not necessarily correspond to the actual value that has been realized or will be realized in the future with respect to these awards.
| (a) · (b) · (c) · (d) · (e) · (f) · (g) · (h) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Name and Principal Position · Year · Salary ($) · Bonus ($) (1) · Stock Awards ($)(2) · Option Awards ($)(2) · All Other ($) · Total ($) | ||||||||||
| Jeffrey Parker, CEO | 2024 | $260,000 | $350,000 | $ | - | $ | - | $24,000 | 3 | $634,000 |
| 2023 | 260,000 | 111,000 | 60,020 | - | 24,000 | 3 | 455,020 | |||
| Cynthia French, CFO | 2024 | 180,000 | 100,000 | - | - | - | 280,000 | |||
| 2023 | 180,000 | 45,000 | - | - | - | 225,000 | ||||
| 1. | Bonuses for 2024 performance were approved by the compensation committee and paid in January 2025. |
| 2. | The amounts represented in columns (e) and (f) represent the full grant date fair value of equity awards in accordance with ASC 718. Refer to Note 14 to the consolidated financial statements for the year ended December 31, 2024 included in Item 8 for the assumptions made in the valuation of equity awards. |
| 3. | Represents an automobile allowance in the amount of $24,000, paid biweekly. |
Narrative to Summary Compensation Table
Base Salaries and Discretionary Bonuses
The base salaries of our named executive officers, and other key employees, were reduced by approximately 20%, on a voluntary basis, in September 2018 in connection with significant cost reduction measures. Since that time, base salaries have been maintained at those reduced levels. From time to time, our compensation committee will award discretionary cash and/or equity-based bonuses that take into consideration these continued base salary reductions as well as the individual's performance and contribution to the corporate goals. In January 2025, our compensation committee approved the payment of discretionary cash bonuses for Mr. Parker and Ms. French in the amounts of $350,000 and $100,000, respectively. These bonuses were awarded in recognition of the officers' significant contribution to our strategic initiatives, including Mr. Parker's leadership in overseeing our patent litigation efforts and supporting our financial stability and Ms. French's role in maintaining compliance with regulatory requirements and reducing costs associated with outside professional services. The bonuses also partially offset the voluntary 20% base salary reductions since 2018 as part of the officers' efforts to support the Company during a period of significant challenges. The bonuses reflect the compensation committee's intent to appropriately compensate these executives for their leadership and sustained commitment to advancing the Company's goals.
Employment and Non-Compete Agreements
We do not have employment agreements in place for our executives. We do have non-compete arrangements in place with all of our employees, including our executives, that impose post-termination restrictions on (i) employment or consultation with competing companies or customers, (ii) recruiting or hiring employees for a competing company, and (iii) soliciting or accepting business from our customers.
Employee Benefits and Perquisites
Our named executive officers are eligible to participate in our health and other benefit plans to the same extent as our other full-time employees. We did not make any employer contributions to our tax-qualified defined contribution 401(k) plan in 2023, and the plan, which was available to all of our full-time employees, was terminated in June 2023. We generally do not provide our named executive officers with perquisites or other personal benefits that are not afforded to all full-time employees, with the exception of a $24,000 annual vehicle allowance provided for our chief executive officer.
Policies and Practices Related to the Grant of Equity Awards
From time to time, we grant equity awards, including stock options, to our employees, including our named executive officers. Historically, we have typically granted new-hire option awards on a new hire's employment start date. Also, non-employee directors have historically received annual equity awards during or about the first month of each calendar year, pursuant to our non-employee director compensation policy. We do not otherwise maintain any written policies on the timing of our equity awards. Our compensation committee considers whether there is any material nonpublic information ("MNPI") about our company when determining the timing of equity awards and does not seek to time the grant of equity awards in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation. During the year ended December 31, 2024, we did not grant any stock option or other equity awards to our named executive officers.
Independent Compensation Consultant
In December 2024, our compensation committee retained an independent consultant, Alliant Human Capital ("Alliant"), to conduct a competitive review and assessment of our executive compensation program and to make recommendations for both our executive compensation and non-employee director compensation programs on a going forward basis. Our compensation committee is in the process of reviewing Alliant's findings.
Outstanding Equity Awards at Fiscal Year End
The following table summarizes information concerning the outstanding equity awards, including unexercised options, unvested stock and equity incentive awards, as of December 31, 2024 for each of our Executives:
| Option Awards | |||||
|---|---|---|---|---|---|
| Number of securities underlying unexercised options (#) exercisable · Number of securities underlying unexercised options (#) unexercisable · Option Exercise Price ($) · Option Expiration Date | |||||
| Name · (a) · (b) · (c) · (d) | |||||
| Jeffrey Parker | 2,660,000 | 1,4 | - | 0.17 | 8/7/2026 |
| 8,000,000 | 2 | - | 0.54 | 1/11/2026 | |
| Cynthia French | 870,550 | 1 | - | 0.17 | 8/7/2026 |
| 150,000 | 3 | - | 0.33 | 2/9/2027 | |
| 1,000,000 | 2 | - | 0.54 | 1/11/2026 | |
| 1 | Options vested over eight equal quarterly periods from September 1, 2019 to June 1, 2021. |
| 2 | Options vested over eight equal quarterly periods from March 31, 2021 to December 31, 2022. |
| 3 | Options vested 50% on grant date and the remaining 50% over four equal quarterly periods from May 9, 2020 to May 9, 2021. |
| 4 | Number of securities underlying exercisable options is net of 3.3 million share options gifted for no consideration by Mr. Parker in January 2021. |
Director Compensation
Since September 2018, the Board compensation program has consisted exclusively of equity-based compensation, generally awarded annually, in the form of nonqualified stock options, RSUs, or a combination thereof. Unvested director equity compensation awards are forfeited if the director's services are terminated for any reason. In January 2023, the Board formalized its non-employee director compensation program whereby (i) non-employee directors will continue to solely receive share-based compensation for board and committee service, (ii) share-based compensation will be awarded annually on or about the first month of each year, (iii) the grant-date fair value of non-employee director awards for annual board service shall not exceed $80,000 for board service and no more than $20,000 additional for serving on the audit committee, (iv) the awards shall vest over four equal quarters and expire no more than seven years after grant date, and (v) any unvested awards shall be forfeited upon a director's termination of service for any reason.
In December 2024, the compensation committee engaged a compensation consultant to evaluate its executive and director compensation programs and make recommendations on a going-forward basis. The compensation committee is in the process of reviewing the consultant's findings and, accordingly, has delayed issuance of the annual director equity award that would typically be issued in January 2025.
We reimburse our non-employee directors for their reasonable expenses incurred in attending meetings where applicable and we encourage participation in relevant educational programs for which we reimburse all or a portion of the costs incurred for these purposes.
Directors who are also our employees are not compensated for serving on our Board. Information regarding compensation otherwise received by our directors who are also named executive officers is provided under “Executive Compensation.”
The following table summarizes the compensation for each of our non-employee directors who served as a director for any portion of the year ended December 31, 2024.
| Name · Stock Awards($) · Option Awards($) 1 · Total ($) | ||||
|---|---|---|---|---|
| (a) · (b) · (c) · (d) | ||||
| Sanford Litvack 2 | $ | - | $50,746 | $50,746 |
| Paul Rosenbaum 3 | - | 50,746 | 50,746 | |
| Robert Sterne 3 | - | 50,746 | 50,746 | |
| Lewis Titterton 4 | - | 50,746 | 50,746 | |
| 1. | The amounts represented in columns (b) and (c) represent the full grant date fair value of share-based awards in accordance with ASC 718. Refer to Note 14 of the consolidated financial statements included in Item 8 for the assumptions made in the valuation of stock awards. |
| 2. | At December 31, 2024, Mr. Litvack has an aggregate of 1,175,000 nonqualified stock options outstanding, of which 1.106,250 are exercisable. |
| 3. | At December 31, 2024, Messrs. Rosenbaum and Sterne each have 2,330,000 nonqualified stock options outstanding, of which 2,261,250 are exercisable. |
| 4. | At December 31, 2024, Mr. Titterton has 937,500 nonqualified stock options outstanding, of which 568,750 are exercisable. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.